

## Veröffentlichungen

Fleischer S, Drexler HHS, Wittmann S, Groß US, **Clanget C**, Schulte HM  
**Primary hypoparathyroidism due to a novel germline mutation in the CASR gen – a case study.**  
Med. Genet. 2009; 21 (1): P009, 81

**Clanget C**, Hinke V, Lange S, Fricke R, Botko R, Pfeilschifter J.  
**Patterns of hormone replacement therapy in a population-based cohort of postmenopausal German women. Changes after HERS II and WHI.**  
Exp Clin Endocrinol Diabetes. 2005 Oct;113(9):529-33.

Walter-Sack I, **Clanget C**, Ding R, Goeggelmann C, Hinke V, Lang M, Pfeilschifter J, Tayrouz Y, Wegscheider K.  
**Assessment of levothyroxine sodium bioavailability: recommendations for an improved methodology based on the pooled analysis of eight identically designed trials with 396 drug exposures.**  
Clin Pharmacokinet. 2004;43(14):1037-53.

Hinke V, **Clanget C**, Botko R, Kallenbach S, Löscher S, Richter A, Schumacher J, Schatz H, Pfeilschifter J.  
**The Bochum Postmenopause Study.**  
Exp Clin Endocrinol Diabetes. 2003 Apr; 111(2):A2.

**Clanget C**, Hinke V, Pfeilschifter J.  
**Behandlung der euthyreoten Struma nodosa mit einer individuellen, TSH-adaptierten Kombination aus L-Thyroxin und 150µg Jodid. Ergebnisse einer einjährigen prospektiven Beobachtungsstudie.**  
Der Kassenarzt. 2002; 42 (28/29): 33-36

Goeggelmann C, **Clanget C**, Ding R, Hinke V, Lang M, Pfeilschifter J, Tayrouz Y, Walter-Sack I, Wegscheider K.  
**Bioequivalence assesment of endogenous compounds like hormones: Eight levothyroxine (L-T4) formulations.**  
Eur J Clin Pharmacol. 2002; 58(7): S94, 88

Hinke V, Seck T, **Clanget C**, Scheidt-Nave C, Ziegler R, Pfeilschifter J.  
**Association of transforming growth factor-beta1 (TGFbeta1) T29 --> C gene polymorphism with bone mineral density (BMD), changes in BMD, and serum concentrations of TGF-beta1 in a population-based sample of postmenopausal german women.**  
Calcif Tissue Int. 2001 Dec;69(6):315-20.

**Clanget C**, Seck T, Hinke V, Wuster C, Ziegler R, Pfeilschifter J.  
**Effects of 6 years of growth hormone (GH) treatment on bone mineral density in GH-deficient adults.**  
Clin Endocrinol (Oxf). 2001 Jul;55(1):93-9.

Hinke V, Seck T, **Clanget C**, Scheidt-Nave C, Ziegler R, Pfeilschifter J.  
**A TGF-β1 Gene polymorphism is associated with bone mineral density and bone loss in postmenopausal women.**  
Exp Clin Endocrinol Diabetes. 2000; 108(Suppl.1): S56.

**Clanget C**, Seck T, Hinke V, Wüster C, Ziegler R, Pfeilschifter J.  
**Long Term Effects of Growth Hormone (GH) on Bone Mineral Density in GH-deficient Adults.**  
Exp Clin Endocrinol Diabetes. 2000; 108(Suppl.1): S44.

**Clanget C**, Frank M, Grauer MT, Ruprecht KW.  
**Die Retinopathia diabetica in Abhängigkeit von der Diabetesbehandlung bei Typ 1 Diabetikern.**  
Der Ophthalmologe. 1999; Sep; 96(Suppl. 1) S135